Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting Claudin-1 (CLDN1), a protein that plays a key role in solid tumors and organ fibrosis. Founded in 2019 by Professor Thomas Baumert following more than 15 years of pioneering research at the University of Strasbourg and Inserm, Alentis is advancing a pipeline of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) designed to selectively bind exposed CLDN1 in tumor and fibrotic tissue. The company's lead programs, ALE.P02 and ALE.P03, are ADCs in clinical development for CLDN1-positive solid tumors, and ALE.F02 (Lixudebart) targets multi-organ fibrosis. Alentis has received FDA Fast Track designation for ALE.P02 and raised $181.4 million in a Series D financing co-led by Novo Holdings to advance its clinical pipeline.